Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-09-19
2006-09-19
Saunders, David (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C439S916000, C530S387900, C530S388260, C530S388900
Reexamination Certificate
active
07108992
ABSTRACT:
The present invention provides methods for detecting activation of ATM kinase, DNA damage, and DNA damaging agents. Further provided are antibodies which specifically recognize the phosphorylation state of Ataxia Telangiectasia-Mutated (ATM) kinase. Methods of identifying agents which modulate the activation and activity of ATM kinase are also provided.
REFERENCES:
patent: 2233970 (1941-03-01), Andersag et al.
patent: 4181725 (1980-01-01), Voorhees et al.
patent: 4260615 (1981-04-01), Raether et al.
patent: 4284627 (1981-08-01), Raether et al.
patent: 4421920 (1983-12-01), Baudouin et al.
patent: 4431807 (1984-02-01), Strube et al.
patent: 5134168 (1992-07-01), Bitonti et al.
patent: 5242932 (1993-09-01), Gandy et al.
patent: 5278173 (1994-01-01), Davis
patent: 5314894 (1994-05-01), Stecher et al.
patent: 5340803 (1994-08-01), Rubin
patent: 5430039 (1995-07-01), Roberts-Lewis et al.
patent: 5596002 (1997-01-01), Hofheinz et al.
patent: 5599681 (1997-02-01), Epstein et al.
patent: 5624938 (1997-04-01), Pernis
patent: 5635515 (1997-06-01), Chauffert et al.
patent: 5639761 (1997-06-01), Francois et al.
patent: 5668149 (1997-09-01), Oroszlan et al.
patent: 5948791 (1999-09-01), Hofheinz et al.
patent: 6348311 (2002-02-01), Kastan et al.
patent: 6387640 (2002-05-01), Kastan et al.
patent: 6417177 (2002-07-01), Nelson
patent: 6475518 (2002-11-01), Baumgart et al.
patent: 6579898 (2003-06-01), Humphrey
patent: 6670167 (2003-12-01), Chen et al.
patent: 6808877 (2004-10-01), Wang et al.
patent: 6916627 (2005-07-01), Kastan et al.
patent: 2002/0044919 (2002-04-01), Yu
patent: 2002/0169140 (2002-11-01), Prendergast
patent: 2003/0157572 (2003-08-01), Kastan et al.
patent: 2004/0092583 (2004-05-01), Prendergast
patent: WO 98/56391 (1998-12-01), None
patent: WO-01/52868 (2001-07-01), None
patent: WO-02/13826 (2002-02-01), None
patent: WO-03/013535 (2003-02-01), None
Cruse et al, Illustrated Dictionary of Immunology, CRC Press, Inc., 1995. p. 316.
Alligood et al., “Ionoclonal Antibodies Generated Against Recombinant ATM Support Kinase Activity”, Hybridoma 2000 19(4):317-321.
Banin et al., “Enhanced Phosphorylation of p53 by ATM in Response to DNA Damage”, Science 1998 281:1674-1677.
Canman et al., “Activation of the ATM Kinase by lonizing Radiation and Phosphorylation of p53”, Science 1998 281:1677-1679.
Hartwell et al., “Cell Cycle Control and Cancer”, Science 1994 266:1821-1828.
Johnson et al., “Active and Inactive Protein Kinases:Structural Basis for Regulation”, Cell 1996 85:149-158.
Kastan Michael, “Ataxia-Telangiectasia—Broad Implications for a Rare Disorder”, N. Engl. J. Med. 1995 333(10):662-663.
Kastan et al., “The Many Substrates and Functions of ATM”, Molecular Cell Biology 2000 1:179-186.
Kim et al., “Substrate Specificities and Identification of Putative Substrates of ATM Kinase Family Members”, J. Biol. Chem. 1999 274(53):37538-37543.
Lim et al., “ATM phosphorylates p95
bs1 in an S-phase checkpoint pathway”, Nature 2000 404:613-617.
Morgan et al., “Fragments of ATM Which Have Dominant-Negative or Complementing Activity”, Molecular and Cellular Biology 1997 17(4):2020-2029.
Sarkaria et al., “Inhibition of Phosphoinositide 3-Kinase Related Kinases by the Radiosensitizing Agent Wortmannin”, Cancer Research 1998 58:4375-4382.
Shiloh et al., “ATM:Genome Stability, Neuronal Development, and Cancer Cross Paths”, Advances in Cancer Research 2000 83:209-253.
Burkard et al., “Antiteratogenic and anticarcinogenic effects of X-rays in urethane-treated NMRI mice”, Int. J. Radiat. Biol. 1987 51(6):1031-1039.
Geser et al., “Effect of a Malaria Suppression Program on the Incidence of African Burkitt's Lymphoma”, American Journal of Epidemology 1989 129(4):740-753.
Bielicky and Zák, “The protective effect of chloroquine disphosphate”, Strahlentherapie 1967 133(2):307-311 Summary Only Considered.
Angele, S. and Hall, J., The ATM gene and breast cancer: is it really a risk factor? Mutation Res. 462:167-178, 2000.
Al-Herz, A., et al., “Survey of antimalarial use of lupus pregnancy and lactation”, J. Rheumatol., 2002, vol. 29; pp. 700-706.
Arnold, A.M., et al., “Interaction of VP16-213 with the DNA repair antagonist chloroquine,” Cancer Chemotherapy and Pharmacology, 1982, vol. 7, pp. 123-126.
Azzam, E.I., “Low dose ionizing radiation decreases the frequency of neoplastic transformation to a level below the spontaneous rate in C3h 10T ½ cells”, Radiation Res., 1996, vol. 146, pp. 369-373.
Bakkenist, C.J., and Kastan, M.B., “DNA damage activates ATM through intermolecular autophosphorylation and dimer dissocation”, Nature, 2003, vol. 421, pp. 499-506.
Bartkova, J., et al., “DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis”, Nature, 2005, vol. 434, pp. 864-869.
Bartkova, J., et al., “ATM activation in normal human tissues and testicular cancer”, Cell Cycle, vol. 4(6), pp. 838-845, 2005.
Bhattarcharjee, D., “Role of radioadaptation on radiation-induced thymic lymphoma in mice”, Mutation Res., 1996, vol. 358, pp. 231-235.
Bielicky T., et al., “Effect of chloroquine-diphosphate administration on the skin damage in guinea pigs caused by x-ray irradiation,” Journal of Investigative Dermatology, 1966, 47(2), pp. 73-77.
Boniver, J., et al., “Cellular events in radiation-induced lymphomagenesis”, Int. J. Radiat. Biol., 1990, vol.57, pp. 693-698.
Briceno, Eduardo, et al., “Therapy of glioblastoma multifome improved by the antimutagenic chloroquine”, Neurosurg. Focus, 2003, vol. 14, No. 2, pp. 1-6.
Cadet, J. et al., “Radiation-induced DNA damage: formation, measurement, and biochemical features”, Environ Pathol Toxicol Oncol., 2004, vol. 23, pp. 33-43.
Cobreros et al., “Modifiers of radiation action on DNA screened by analytical ultracentrifugation,” Radiation Research, 1982, 92(2), pp. 255-267.
Collis, S.J., et al., “Evasion of early cellular response mechanisms following low level radiation-induced DNA damage ”, The Journal of Biological Chemistry, Nov. 26, 2004, vol. 279, No. 48, pp. 49624-49632.
Costedoat-Chalumeau, N., et al., “Safety of hydroxchloroquine in pregnant patients with connective tissue diseases”, Arthritis Rheumatism, 2003, vol. 48, pp. 3207-3211.
Ducharme, J., et al., “Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements,” Clinical Pharmacokinetics, 1996, 31(4), pp. 257-274.
Feinendegen, L.E., et al., “Intracellular stimulation of biochemical control mechanisms”, Healthy Physics, 1987, vol. 52, pp. 663-669.
Fernandez, Y., et al., “Effect of systemic lupus erythematosus (SLE) treatment drugs on G1-101A breast tumor cell growth,” Life Sciences, 2000, vol. 67, pp. 567-575.
Freeman, R.G., et al., “Skin cancer and the sun,” CA Cancer J Clin., 1967, vol. 17, No. 5, pp. 231-239.
Frigerio, N.A., et al., “Carcinogenic and genetic hazard from background radiation. Biological and environmental effects of low-level radiation”, IAEA, 1976, vol. II, pp. 385-393.
Haberkorn, A., et al., “Antimalarial activity in animals of the optical isomers of chloroquine diphosphate”, Trop Med Parasitol, 1979, vol. 30, pp. 308-312.
Hagihara, H., et al., “Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107,” Cancer Research, Jan. 15, 2000, vol. 60, pp. 230-234.
Horejsi, Z., et al., “Distinct functional domains of Nbs1 modulate the timing and magnitude of ATM activation after low doses of ionizing radiation”, Oncogene, 2004, vol. 23, pp. 3122-3127.
Ikushima, T., et al., “Radioadaptive response; Efficient repair of radiation induced DNA dmaage in adapted cells”, Mutation Res., 1996, vol. 358,
Bakkenist Christopher
Kastan Michael B.
DArby & Darby
Saunders David
St. Jude Children's Research Hospital
LandOfFree
ATM kinase compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ATM kinase compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ATM kinase compositions and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3544181